SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
Company: REGENERON PHARMACEUTICALS, INC.
Filing Type: Form 13F Information Table
Reporting Period: The filing text does not provide a clear value for the specific reporting period end date, though metadata suggests "2026 Jun 30". The document lists holdings as of the filing date.
Key Financial Metrics and Holdings
This filing discloses equity holdings managed by Regeneron Pharmaceuticals, Inc. It does not contain revenue, profit, cash flow, or debt metrics for Regeneron itself. The table details the following positions:
| Issuer Name | Title of Class | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|---|
| Adicet Bio, Inc. | Common Stock | 60,511 | $522,819 | Sole |
| Intellia Therapeutics, Inc. | Common Stock | 3,702,995 | $62,654,675 | Sole |
| Parabilis Medicines, Inc. | Common Stock | 4,166,666 | $114,041,648 | Sole |
Material Changes and Outlook
The filing text does not provide data for prior comparable periods, material changes, guidance, management commentary, risks, or contingencies. This document is a static snapshot of holdings at a specific point in time.
Investor Verification Checklist
- Verify the exact reporting period end date, as the text does not explicitly state it.
- Confirm the total aggregate value of all holdings, as only three specific positions are listed in this excerpt.
- Check for any subsequent filings to determine if these positions have been adjusted or liquidated.
- Validate the "Sole" voting authority status for each position against the company's proxy statements.